KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Net Margin (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Net Margin for 15 consecutive years, with 1.92% as the latest value for Q4 2025.

  • On a quarterly basis, Net Margin fell 1075.0% to 1.92% in Q4 2025 year-over-year; TTM through Dec 2025 was 5.36%, a 1654.0% decrease, with the full-year FY2025 number at 5.36%, down 1652.0% from a year prior.
  • Net Margin was 1.92% for Q4 2025 at Supernus Pharmaceuticals, up from 23.51% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 21.94% in Q3 2024 to a low of 23.51% in Q3 2025.
  • A 5-year average of 4.93% and a median of 4.48% in 2022 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: soared 3232bps in 2024, then crashed -4544bps in 2025.
  • Supernus Pharmaceuticals' Net Margin stood at 1.54% in 2021, then skyrocketed by 892bps to 15.22% in 2022, then tumbled by -95bps to 0.69% in 2023, then surged by 1176bps to 8.83% in 2024, then crashed by -122bps to 1.92% in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Net Margin are 1.92% (Q4 2025), 23.51% (Q3 2025), and 13.6% (Q2 2025).